Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

William McEwan, Ph.D., spent years unraveling how an antiviral protein, tripartite motif-containing 21 (TRIM21), protects our ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis (MASH) after three ...

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...